Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies - Related Studies

Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies

This study has been suspended.

Study NCT00070239. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer
		Head and Neck Cancer
		Intraocular Melanoma
		Kidney Cancer
		Leukemia
		Lung Cancer
		Lymphoma
		Malignant Mesothelioma
		Melanoma (Skin)
		Sarcoma
		Small Intestine Cancer

2	Additional conditions recognized in this trial
		Breast Neoplasms
		Carcinoma, Renal Cell
		Duodenal Neoplasms
		Eye Neoplasms
		Head and Neck Neoplasms
		Hematologic Neoplasms
		Ileal Neoplasms
		Intestinal Neoplasms
		Jejunal Neoplasms
		Kidney Neoplasms
		Lung Neoplasms
		Melanoma
		Mesothelioma
		Multiple Myeloma
		Neoplasms, Plasma Cell

3	More general conditions related to this trial
		Adenocarcinoma
		Adenoma
		Blood Protein Disorders
		Breast Diseases
		Carcinoma
		Cardiovascular Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Duodenal Diseases
		Eye Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Ileal Diseases
		Immune System Diseases
		Immunoproliferative Disorders
		Intestinal Diseases
		Jejunal Diseases
		Kidney Diseases
		Lung Diseases
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Mesothelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Nevi and Melanomas
		Paraproteinemias
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Skin Diseases
		Thoracic Neoplasms
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms
		Vascular Diseases

4	Interventions listed in this trial
		alvocidib

5	Additional drug interventions recognized in this trial
		Flavopiridol

6	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Growth Inhibitors
		Growth Substances
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Dana-Farber Cancer Institute
		National Cancer Institute (NCI)